[ad_1] Apellis Pharmaceuticals (APLS) said Friday the Food and Drug Administration will review its new eye-disease drug in February, and APLS stock surged. X The new review date is actually a delay at Apellis’ behest. Earlier this month, Apellis said it planned to send 24-month test data from studies called Derby and Oaks in its